Literature DB >> 7387761

Antimicrobial activity of netilmicin in comparison with gentamicin, sisomicin, tobramycin, and amikacin and their resistance patterns.

I Braveny, J Voeckl, K Machka.   

Abstract

The antimicrobial activity of netilmicin, gentamicin, sisomicin, tobramycin and amikacin was determined by means of the microdilution test. 1000 fresh isolates of strains of Staphylococcus aureus, Pseudomonas aeruginosa and 7 species of the Enterobacteriaceae were tested. The activities were compared and cross-resistances were analyzed which appeared among the various drugs. Against amikacin, only 0.5% of all strains (3 P. aeruginosa, 1 S. aureus, 1 P. mirabilis) were resistant. Of the other drugs, netilmicin was the most active drug against S. aureus, Klebsiella spp., Enterobacter spp. and Escherichia coli. Against E. coli, too, sisomicin showed its best activity, and further against Citrobacter spp., Proteus spp. and P. aeruginosa. A total of 12% of all pathogens was gentamicin-resistant. With one exception, these pathogens showed cross-resistance to at least one of the other drugs. In 39% of the cases a cross-resistance between gentamicin and tobramycin was noted, in 26% a gentamicin-tobramycin-sisomicin cross-resistance, in 17% gentamicin-tobramycin-sisomicin-netilmicin cross-resistance, in 11% a gentamicin-sisomicin-netilmicin cross-resistance. A complete cross-resistance was observed between gentamicin and sisomicin with S. aureus, Serratia spp. and Proteus mirabilis, between gentamicin and tobramycin with E. coli, Citrobacter spp. and Enterobacter spp.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7387761

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  8 in total

1.  In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin.

Authors:  D Milatovic; C Wallrauch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-08       Impact factor: 3.267

2.  Comparative synergistic activity of ceftriaxone-piperacillin versus ceftriaxone-netilmicin.

Authors:  K Machka; R Dietz
Journal:  Eur J Clin Microbiol       Date:  1983-10       Impact factor: 3.267

3.  Prophylaxis of postoperative lumbar spondylodiscitis.

Authors:  P M Zink; A M Frank; A E Trappe
Journal:  Neurosurg Rev       Date:  1989       Impact factor: 3.042

4.  Cefsulodin pharmacokinetics and otitis media.

Authors:  P Federspil; W Schätzle; E Tiesler
Journal:  Arch Otorhinolaryngol       Date:  1982

5.  Pharmacokinetic assessment of netilmicin in newborns and older children.

Authors:  T Bergan; H Michalsen
Journal:  Infection       Date:  1982       Impact factor: 3.553

6.  Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model.

Authors:  J Blaser; B B Stone; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

Review 7.  Netilmicin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; S Chaplin; R H Sayce; K L Goa
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

8.  Comparative synergistic activity of netilmicin-piperacillin versus gentamicin-piperacillin.

Authors:  K Machka; W Baierl; I Braveny
Journal:  Eur J Clin Microbiol       Date:  1982-08       Impact factor: 3.267

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.